Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide
Obesity represents a major contributor to cardiovascular disease burden, particularly in resource-limited settings where prevention, early detection, and long-term management remain challenging. Excess adiposity promotes cardiometabolic dysfunction through interconnected pathways involving insulin resistance, chronic low-grade inflammation, dyslipidemia, neurohormonal activation, and adverse cardiac remodeling, ultimately increasing the risk of heart failure, ischemic heart disease, stroke, and major adverse cardiovascular events. Among emerging therapeutic targets, incretin-based pathways have gained particular attention because they address both weight reduction and cardiovascular risk modification. Semaglutide, a glucagon-like peptide-1 receptor agonist, has become one of the most clinically relevant agents in this field, with evidence showing substantial reductions in body weight and improvements in glycemic control, visceral adiposity, systemic inflammation, blood pressure, and cardiometabolic risk markers. Data further support the potential role of semaglutide in reducing cardiovascular events, including among individuals with obesity and established cardiovascular disease without type 2 diabetes. The aim of the review is to synthesize current mechanistic and clinical evidence on semaglutide as an emerging therapeutic strategy in obesity management for cardiovascular risk reduction, while briefly contextualizing its role among other novel anti-obesity pharmacotherapies. Particular attention is also given to the relevance of semaglutide in resource-limited settings. Understanding organ-specific mechanisms and prioritizing scalable interventions may support more effective cardiovascular disease risk reduction strategies in obesity within resource-constrained healthcare systems.
Authors
- Antonia Anna Lukito (ORCID: https://orcid.org/0000-0001-8519-8949)
- Anwar Santoso (ORCID: https://orcid.org/0000-0001-8247-4151)
- Erwinanto Erwinanto
- Badai Bhatara Tiksnadi (ORCID: https://orcid.org/0000-0002-0314-5577)
- Jordan Bakhriansyah (ORCID: https://orcid.org/0000-0002-9874-2250)
- Habibie Arifianto (ORCID: https://orcid.org/0000-0001-5145-1299)
- Yudi Her Octaviono
- Ade M. Ambari
- Haryadi Haryadi
- Siska S. Danny
Institutions
- Pelita Harapan University (ID)
- Sebelas Maret University (ID)
- University of Surabaya (ID)
- Universitas Airlangga (ID)
- University of Indonesia (ID)
- Dr. Hasan Sadikin General Hospital (ID)
- Universitas 45 Surabaya (ID)
- Padjadjaran University (ID)
Publication Details
- Journal
- Narra X
- Published
- 2026-11-16
- DOI
- https://doi.org/10.52225/narrax.v4i3.381
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk